[Assessment of value and risks of external treatment with clobetasol-17-propionate (Dermovate)].
D000287:Administration, Topical; D001623:Betamethasone / Q000031:analogs & derivatives*; D001624:Betamethasone Valerate / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D002990:Clobetasol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D004311:Double-Blind Method; D004341:Drug Evaluation; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D010913:Pituitary-Adrenal System / Q000187:drug effects; D011565:Psoriasis / Q000188:drug therapy*
D001623:Betamethasone; D001624:Betamethasone Valerate; D002990:Clobetasol; D006854:Hydrocortisone
Waardebepaling en risicoschatting van de uitwendige behandeling met clobetasol-17-propionaat (Dermovate).